Acutus Medical - AFIB Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acutus Medical in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AFIB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AFIB, but not buy additional shares or sell existing shares.
View AFIB analyst ratings or view top-rated stocks.

3 analysts have issued 1-year price targets for Acutus Medical's shares. Their AFIB share price forecasts range from $1.50 to $2.50. On average, they predict the company's share price to reach $2.00 in the next twelve months. This suggests a possible upside of 7.0% from the stock's current price.
View analysts price targets for AFIB or view top-rated stocks among Wall Street analysts.

Acutus Medical's stock was trading at $1.15 at the start of the year. Since then, AFIB stock has increased by 62.6% and is now trading at $1.87.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our AFIB earnings forecast.

Acutus Medical, Inc. (NASDAQ:AFIB) announced its quarterly earnings data on Thursday, November, 10th. The company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.11. The company earned $3.64 million during the quarter, compared to analyst estimates of $3.52 million. Acutus Medical had a negative net margin of 545.51% and a negative trailing twelve-month return on equity of 100.62%.

Acutus Medical updated its FY 2022 earnings guidance on Sunday, January, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $16.10 million-$16.30 million, compared to the consensus revenue estimate of $15.70 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Acutus Medical investors own include Oak Street Health (OSH), Alibaba Group (BABA), Checkmate Pharmaceuticals (CMPI), Salesforce (CRM), Walt Disney (DIS), DocuSign (DOCU), Marvell Technology (MRVL), NVIDIA (NVDA), Tesla (TSLA) and Twilio (TWLO).

(AFIB) raised $126 million in an initial public offering (IPO) on Thursday, August 6th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, BofA Securities and William Blair acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

Acutus Medical trades on the NASDAQ under the ticker symbol "AFIB."

Acutus Medical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include James F Hinrichs, Orbimed Advisors Llc and R Scott Huennekens.
View institutional ownership trends.

Shares of AFIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AFIB stock can currently be purchased for approximately $1.87.

Acutus Medical (NASDAQ:AFIB) has a market capitalization of $53.21 million and generates $15.76 million in revenue each year. The company earns $-117,680,000.00 in net income (profit) each year or ($3.10) on an earnings per share basis.

The company employs 291 workers across the globe.

Acutus Medical's mailing address is 2210 FARADAY AVE SUITE 100, CARLSBAD CA, 92008. The official website for the company is www.acutusmedical.com. The company can be reached via phone at 442-232-6080, via email at investors@acutusmedical.com, or via fax at 442-232-6081.